Monoclonal antibodies (mAbs) are highly specific, laboratory-produced antibodies designed to target a single specific epitope or binding site on an antigen. Unlike polyclonal antibodies, which are a ...

In 1975, Georges Köhler and César Milstein, biochemists from the Medical Research Council Laboratory of Molecular Biology, published a paper in Nature about a hybridoma technology that enabled the ...

Antibodies are a critical feature of the human adaptive immune response. New immunotherapies require the production of selective and non-autoimmunogenic antibodies. These engineered antibodies can ...

Researchers developed a machine learning model that predicts high-yield antibody-producing cell lines early in manufacturing, ...

Antibodies are the number one immune cells that fight against infection and diseases. However, beyond their natural usage, biochemistry has devised several ways in which these antibodies can be ...

Researchers at the Terasaki Institute developed a novel microfluidic biosensing platform to monitor monoclonal antibody secretion in real time. The system integrates a photonic crystal biosensor with ...

The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...

Industrial yeasts are a powerhouse of protein production, used to manufacture vaccines, biopharmaceuticals, and other useful ...